Pharmaceutical company Novartis AG invested $9.996 billion in Research and Development in 2022, an increase of 4.8% year-on-year. In April 2022, the company announced the
The global oncology treatment market grew from $93.7 billion in 2016 to $150.3 billion in 2020, according to Hutchmed. According to the same source, the
Lung cancer patients face median five-year survival rates of just 17% (compared to 89% for breast cancer and 98% for prostate cancer). Why this wide
Tagrisso ranked # 1 among AstraZeneca’s top medicines by the amount of its sales in 2020. Sales of this drug totaled $ 4.328 million last
Pharmaceutical company Novartis AG invested $9.996 billion in Research and Development in 2022, an increase of 4.8% year-on-year. In April 2022, the company announced the
The global oncology treatment market grew from $93.7 billion in 2016 to $150.3 billion in 2020, according to Hutchmed. According to the same source, the
Lung cancer patients face median five-year survival rates of just 17% (compared to 89% for breast cancer and 98% for prostate cancer). Why this wide
Tagrisso ranked # 1 among AstraZeneca’s top medicines by the amount of its sales in 2020. Sales of this drug totaled $ 4.328 million last
